10 August 2017 13:30 BST

Publication of Prospectus

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:

Base Prospectus for the AstraZeneca PLC U.S. $5,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

The last drawdown under the EMTN programme was in 2016.

To view the full document, please paste the following URL into the address bar of your browser.

http://www.rns-pdf.londonstockexchange.com/rns/6730N_-2017-8-10.pdf

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

http://www.morningstar.co.uk/uk/NSM

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Adrian Kemp

Company Secretary

AstraZeneca PLC